Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The
treatment of PsA has changed substantially over the past 10 years. Clinical practice …

ABSTRACT Introduction Psoriatic arthritis (PsA) and spondyloarthritis (SpA) are
inflammatory arthritides associated with progressive damage, deformity and morbidity …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Objective To characterize psoriatic arthritis (PsA) patients with dactylitis or enthesitis and
evaluate the associations of these manifestations with disease activity and patient‐reported …

ABSTRACT Objective Psoriatic arthritis (PsA) is a heterogeneous inflammatory disorder that
requires targeted treatment based on clinical manifestations, symptom severity …

Abstract Objective The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the
most consistent literature to indicate the best strategy for the second-line biologic choice in …

Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis
(PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two …

Objective. Biologic agents with different mechanisms of action [inhibitors of tumor necrosis
factor-α (TNF-α), interleukin (IL)-12/23, and IL-17] showed efficacy in randomized controlled …

Psoriasis is an autoimmune and inflammatory skin disease affecting around 2–3% of the
world's population. Patients with psoriasis need extensive treatments with global …